1. ICH, Guidance for Industry: Q3A Impurities in New Drug Substances, U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER),2008
2. ICH, Guidance for Industry: Q3B(R2) Impurities in New Drug Products, U.S. Dept. Of Health and Human Services, Food and Drug Administration,2006
3. Assuring quality of drugs by monitoring impurities;Ahuja;Adv. Drug Del. Rev.,2007
4. Critical review of reports on impurity and degradation product profiling in the last decade;Görög;TrAC, Trends Anal. Chem.,2018
5. Impurity investigations by phases of drug and product development;Olsen;TrAC, Trends Anal. Chem.,2018